The FDA has asked for another well-controlled trial to establish the efficacy of reproxalap in dry eye disease.
The FDA has again issued a CRL to Aldeyra regarding the New Drug Application for reproxalap for the treatment of dry eye disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback